Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

immunotherapy

- PMLiVE

Eli Lilly announces positive results for Retevmo in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases in the US

- PMLiVE

AI-supported mammography screening shows promise in breast cancer detection

The AI-supported screening tool detected cancer in 244 people in the study

- PMLiVE

Merck’s Keytruda combination shows promise in late-stage breast cancer study

More than 290,000 people are expected to be diagnosed with breast cancer in the US this year

- PMLiVE

Gilead expands IT partnership with Cognizant in deal worth approximately $800m

It is hoped that the collaboration will enable Gilead to bring its medicines to market faster

EU flag

EMA reports actions to improve EU clinical trials conducted during health emergencies

All proposed actions will be acknowledged by the European Commission, EMA and member states

- PMLiVE

Roche’s spinal muscular atrophy therapy recommended by CHMP for newborns

Evrysdi is already approved in the EU to treat SMA patients aged two months or older

- PMLiVE

Roche partners with Alnylam on hypertension therapy in deal worth up to $2.8bn

Zilebesiran is in phase 2 development to treat hypertension in patients with high-unmet needs

- PMLiVE

Pfizer and Flagship Pioneering sign drug discovery partnership worth up to $7bn

The partners will each invest $50m upfront to develop up to ten new drug candidates

- PMLiVE

US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition

The transaction would mark a significant boost to Pfizer’s oncology pipeline

EU flag

EU establishes €100m funding scheme for projects tackling public health threats

The HERA Invest fund will focus on health emergency prevention and preparedness initiatives

- PMLiVE

Roche’s Ocrevus shows promise as a subcutaneous injection in phase 3 MS trial

The therapy is already approved for certain MS patients as a twice-yearly intravenous infusion

- PMLiVE

Roche’s fixed-duration lymphoma treatment approved by European Commission

Approximately 36,000 people are diagnosed with DLBCL each year in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links